Rec2 AAV Vector Tissue-Specific Promoter Off-Target Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated virus (rAAV) vectors have limited transduction efficiency for adipose tissue and often result in off-target transgene expression, leading to deleterious effects in non-specific tissues.
Innovation Solution
Development of a hybrid serotype Rec2 AAV vector with two expression cassettes, one containing a regulatory element and a transgene linked to a promoter, and the other with a tissue-specific promoter and RNA silencing element to target and restrict transgene expression to specific tissues, such as visceral adipose tissue, minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If naturally occurring AAV serotypes are used for gene delivery, then transduction of adipose tissue can be achieved, but transduction efficiency is low
Solution Approach 1:
The patent modifies the AAV capsid parameters by creating hybrid serotypes (e.g., AAV2/8, AAV2/1) with altered surface properties that enable efficient adipose tissue transduction. These engineered capsids maintain the ability to transduce adipose tissue while achieving high transduction efficiency, resolving the contradiction between naturally occurring low efficiency and the need for reliable gene delivery.
2Productivity
If high dose viral vectors are used to achieve therapeutic effects in adipose tissue, then transduction efficiency improves, but off-target transduction in liver and other tissues increases causing deleterious effects
Solution Approach 1:
The patent employs tissue-specific promoters (e.g., adipose-specific promoters) that confer localized gene expression properties to the transgene. This ensures that even when the viral vector transduces multiple tissue types, the therapeutic gene is expressed only in the target adipose tissue, eliminating off-target harmful effects while maintaining high transduction efficiency in the desired tissue.
Solution Approach 2:
The patent uses tissue-specific regulatory elements as intermediaries between the transduced cells and gene expression. These intermediaries (tissue-specific promoters and microRNAs) act as selective switches that allow gene expression only in adipose tissue, thereby permitting high doses of viral vectors to be used for effective adipose transduction without causing deleterious off-target effects in liver and other tissues.
3Object-affected harmful factors
If adipose tissue specific promoter or micro-RNA targeting sequence is used, then specific transduction of adipose tissue is achieved, but high dose is required to achieve therapeutic effects
Solution Approach 1:
The patent creates composite viral vector systems that combine multiple functional elements: engineered capsids for efficient adipose entry, tissue-specific promoters for selective expression, and microRNA targeting sequences for additional specificity. This composite approach enhances both specificity and therapeutic efficacy, allowing lower doses to achieve therapeutic effects compared to using adipose-specific elements alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Rec2 vector achieves high transduction efficiency in visceral adipose tissue with minimal off-target expression in other tissues, effectively treating conditions like obesity, diabetes, and metabolic syndrome by delivering genes like leptin or IL-15, as demonstrated in mouse models.
Implementation Method 1
a RNA silencing element to target and restrict transgene expression to specific tissues
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2C
AI summary
Disclosed are compositions and methods related to novel adeno-associated virus vectors comprising two expression cassettes, wherein the first cassette comprises a regulatory element and a transgene operatively linked to a promoter; and wherein the second cassette comprises a liver specific promoter operatively linked to a microRNA that targets the regulatory element in the first expression cassette.